Shuang Qiao

Form D signer

Shuang Qiao

Chief Executive Officer at Vivace Therapeutics

Form D signer

Capital raised by Vivace Therapeutics

$17.5M+$17.5M latest round

1 Form D filing · first filed Feb 2025 · San Mateo, CA

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 2 ↗

Career

1 company on file

Vivace TherapeuticsBiotech · San Mateo, CAsince Feb 2025

Chief Executive Officer

Signatory on Vivace Therapeutics's Form D filings · $17.5M raised across 1

Company filings

via EDGAR · Form D for Vivace Therapeutics1

DateCompanyFormAmountRole on filing

Feb 28, 2025Vivace TherapeuticsForm D+$17.5MChief Executive Officer

Form DFeb 28, 2025 · Vivace Therapeutics+$17.5Mas Chief Executive Officer

Overview

Last filing Feb 28, 2025

Shuang Qiao is on file as Chief Executive Officer at Vivace Therapeutics in San Mateo, CA. Vivace Therapeutics has 1 Form D filing on record, $17.5M raised in total. Shuang Qiao appears as a signatory on the company's filings.

Teammates

Vivace Therapeutics · 1

Jake SimsonDirector

Products

Vivace Therapeutics · 1

VT3989Cancer Treatment

VT3989 is an innovative small molecule drug designed to inhibit TEAD autopalmitoylation within the Hippo signaling pathway. This mechanism aims to counteract the effects of pathway dysregulation that can lead to tumorigenesis, particularly in cancers like mesothelioma and other solid tumors characterized by NF2 mutations.